Karyopharm Therapeutics KPTI 深 沪
等待开盘 11-26 09:30:00 美东时间
5.45
-0.110
-1.98%
华盛通- 最 高5.67
- 今 开5.58
- 成交量 11.84万股
- 最 低 5.31
- 昨 收 5.56
- 总市值 9292.74万
- 52周最高 12.45
- 市盈率 静 --
- 换手率 0.69%
- 52周最低 3.51
- 委 比 -68.85%
- 总股本 1705.09万
- 历史最高 735.075
- 量 比 0.96
- 振 幅 6.47%
- 历史最低 5.31
- 每 手 1
- 风险率 2.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
11-04 05:05
Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140.000M-$155.000M vs $149.328M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2025 sales outlook from $140.000 million-$155.000 million to $140.000 million-$155.000 million vs $149.328 million estimate.
11-03 21:01
Karyopharm Therapeutics Q3 EPS $(3.82) Misses $(3.13) Estimate, Sales $44.000M Beat $41.212M Estimate
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(3.82) per share which missed the analyst consensus estimate of $(3.13) by 22.04 percent. This is a 2.05 percent increase over losses of $(3.90) per
11-03 20:32
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Karyopharm Therapeutics Earnings Preview
Karyopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earni...
11-01 05:02
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $21
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $25 to $21.
10-09 20:08
